GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

Leading Exosome Biotechnology Company Advances in Global Effort to Extend Healthy Human Lifespan MIRAMAR, Fla., May 12, 2025 /PRNewswire/ -- Kimera Labs, Inc., the pioneer in therapeutic ...

Synthego has expanded its CRISPR solutions portfolio with the launch of GMP SpCas9, offering researchers a powerful solution to enhance CRISPR-based therapeutic development. The launch of GMP SpCas9 ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

CNW/ -- (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce ...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) technology, today announced plans to present at the upcoming ...

ON24 , a leading intelligent engagement platform provider for B2B sales and marketing, today announced the appointment of David Lee as Chief Marketing Officer (CMO) reporting directly to CEO Sharat ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...